Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: A comparative study

Archives of Neurology

Volumn 66, Issue 5, 2009, Pages 593-599

  Boster, Aaron ^a,b,d   Hreha, Stephanie ^a,b   Berger, Joseph R ^e   Bao, Fen ^a,b   Penmesta, Ramya ^a,b   Tselis, Alexandros ^a,b   Endress, Christina ^a   Zak, Imad ^a   Perumal, Jai ^a,b   Caon, Christina ^a,b   Vazquez, Jose ^c   Tyler, Kenneth L ^f   Racke, Michael K ^d   Millis, Scott ^a   Khan, Omar ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DETROIT MEDICAL CENTER   (United States)

^c Henry Ford Health System Division of Infectious Diseases   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN STEM RESPONSE; BRAIN TISSUE; CEREBELLUM INJURY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; EARLY DIAGNOSIS; ETHNICITY; FEMALE; GRAY MATTER; HEMIPARESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DETERIORATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RADIODIAGNOSIS; RANK SUM TEST; RETROSPECTIVE STUDY; SPINAL CORD; STUDENT T TEST;

ADULT; CENTRAL NERVOUS SYSTEM; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELITIS; OPTIC NEURITIS; PARESIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 66249118663     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.31     Document Type: Article

References (44)

1. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984;2(2):299-313.
2. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1(7712):1257-1260.
3. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain. 1958;81(1):93-111.
4. Aksamit AJ. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist. 2006;12(6):293-298.
5. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4):369-374. (Pubitemid 41132341)
6. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375-381. (Pubitemid 41132342)
7. Stüve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci. 2008;274(1-2):39-41.
8. Ransohoff RM. Natalizumab and PML. Nat Neurosci. 2005;8(10):1275.
9. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924-933. (Pubitemid 43313659)
10. Panzara M, Baldinetti F, Belcher G, et al. Natalizumab utilization and safety in patients with relapsing multiple sclerosis: updated results from TOUCH™ and TYGRIS. Mult Scler. 2008;14(suppl 1):S172 (P488).
11. Gold R. Occurrence of progressive multifocal leukoencephalopathy in two patients relapsing-remitting MS treated with natalizumab: late breaking news. Mult Scler. 2008;14(suppl 1):OP 84.
12. Hauser SL, Waubant E, Arnold DL, et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688.
13. Information for Healthcare Professionals Rituximab (marketed as Rituxan) Information. US Food and Drug Administration Center for Drug Evaluation and Research Web site. http://www.fda.gov/cder/drug/InfoSheets/HCP/rituximab.htm. Published December 2006. Accessed 2008.
14. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8(2):144-146.
15. Davies SL, Moral MA. Spotlight on: clinical development of mycophenolate mofetil in multiple sclerosis. Drug News Perspect. 2006;19(10):632-633.
16. Pagnoux C, Hayem G, Roux F, et al. JC virus leukoencephalopathy complicating Wegner's granulomatosis. Joint Bone Spine. 2003;70(5):376-379. (Pubitemid 37243275)
17. Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis is systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis. 2003;62(1):50-57. (Pubitemid 36005795)
18. Berger JR, Houff S. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurol Res. 2006;28(3):299-305. (Pubitemid 43765116)
19. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 2007;6(5):431-441. (Pubitemid 46551850)
20. Filippi M, Rocca MA, Rizzo G, et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology. 1998;50(5):1289-1293. (Pubitemid 28240341)
21. Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology. 1999;52(3):588-594. (Pubitemid 29075609)
22. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127. (Pubitemid 32591472)
23. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika. 1988;75(2):383-386.
24. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(pt 11):2059-2069. (Pubitemid 27493740)
25. Whiteman ML, Post MJ, Berger JR, Tate LG, Bell MD, Limonte LP. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology. 1993;187(1):233-240. (Pubitemid 23097890)
26. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4(1):59-68. (Pubitemid 28081579)
27. Huang D, Cossoy M, Li M, et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol. 2007;62(1):34-39. (Pubitemid 47235278)
28. Chowdhary S, Chalmers LM, Chamberlain M. Non-HIV-related progressive multifocal leukoencephalopathy (PML): a tertiary cancer center experience. J Neuroimaging. 2007;17(1):69-73. (Pubitemid 46066608)
29. Hoffmann C, Horst HA, Albrecht H, Schlote W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry. 2003;74(8):1142-1144. (Pubitemid 36936402)
30. Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol. 2005;109(4):449-455. (Pubitemid 40637320)
31. Martinez JV, Mazziotti JV, Efron ED, et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology. 2006;67(9):1692-1694.
32. Bernal-Cano F, Joseph JT, Koralnik IJ. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol. 2007;13(5):474-476. (Pubitemid 350104395)
33. Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: similarities and differences. Neurology. 2008;70(5):336-343.
34. Barkhof F, Scheltens P, Frequin ST, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol. 1992;159(5):1041-1047.
35. Morgen K, Jeffries NO, Stone R, et al. Ring-enhancement in multiple sclerosis: marker of disease severity. Mult Scler. 2001;7(3):167-171. (Pubitemid 32651816)
36. Filippi M, Rocca MA. Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases. J Neuroimaging. 2004;14(4):303-313. (Pubitemid 39331612)
37. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56(3):407-415. (Pubitemid 39166560)
38. Kasner SE, Galetta SL, McGowan JC, Grossman RI. Magnetization transfer imaging in progressive multifocal leukoencephalopathy. Neurology. 1997;48(2):534-536. (Pubitemid 27087636)
39. Armand JP, Dousset V, Franconi JM, et al. Progressive multifocal leukoencephalopathy: study of the demyelination by magnetization transfer [in French]. J Radiol. 1997;78(2):131-134. (Pubitemid 27112401)
40. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58(1):65-70. (Pubitemid 32053209)
41. Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology. 2000;215(3):824-830. (Pubitemid 30346024)
42. Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL; Canadian MS/BMT Study Group. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol. 2008;63(2):254-262.
43. Khatri B FR, Koo A, Lynn F, Duda P, Jurgensen S, Panzara M, Giovannoni G. Plasma exchange accelerates the decline of serum natalizumab concentration in patients with multiple sclerosis: results of the Natalizumab PLEX Study. Neurology. 2008;70(11)(supp 1):A227-A228.
44. Stüve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol. 2007;64(2):169-176. (Pubitemid 46256555)